HC Wainwright Brokers Increase Earnings Estimates for ALNY

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities researchers at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a note issued to investors on Monday, November 4th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of ($2.24) per share for the year, up from their previous estimate of ($2.31). HC Wainwright has a “Buy” rating and a $400.00 price target on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.71) EPS, FY2026 earnings at $9.23 EPS, FY2027 earnings at $19.05 EPS and FY2028 earnings at $22.41 EPS.

Several other research analysts also recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Raymond James increased their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Barclays increased their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Six research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $294.50.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $273.01 on Thursday. The company has a 50 day simple moving average of $274.17 and a two-hundred day simple moving average of $229.04. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The firm has a market cap of $35.21 billion, a P/E ratio of -104.20 and a beta of 0.39. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period in the previous year, the business posted $1.15 EPS. The company’s revenue for the quarter was down 33.3% compared to the same quarter last year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALNY. Capital Research Global Investors raised its holdings in shares of Alnylam Pharmaceuticals by 7.3% in the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after buying an additional 214,908 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after purchasing an additional 201,784 shares during the period. Los Angeles Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 92.5% during the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after purchasing an additional 130,482 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Alnylam Pharmaceuticals in the first quarter worth about $18,886,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $20,563,480. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.